The FDA’s Pharmacy Compounding Advisory Committee (PCAC) issued a narrowly positive recommendation on expanding access to compounded, unapproved peptides, setting up additional FDA review decisions. In separate advisory actions, the panel endorsed lifting restrictions for BPC-157 and KPV, while the FDA was also set to vote on other peptides later the same day. The PCAC recommendations are non-binding, but the close vote underscores the regulatory tension between consumer demand for low-studied wellness peptides and the FDA’s expectation of evidence-based safety and effectiveness standards. The agency will still make the final determination on whether to expand the Section 503A Bulk Drug Substances List. For the biotech and pharmaceutical ecosystem, the decision carries downstream implications for compounding workflows, potential demand signals for under-evaluated actives, and how broadly the FDA may allow non-approved substances to enter the US supply chain through pharmacies.